Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market ...
Talking about illness is not easy; however, it helps to raise awareness and emphasizes things that shouldn’t be overlooked ...
The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...
The pharma business also announced that it has already secured final USFDA approvals for Bosutinib Tablets in the 100 mg and ...
Bosutinib Tablets, 400 mg, had an estimated market size of $251 million for the twelve months ended September 2025, ...
Alembic Pharmaceuticals secures USFDA tentative approval for 400 mg Bosutinib tablets, a generic cancer treatment option.
Alembic Pharmaceuticals receives USFDA tentative approval for generic Bosutinib tablets, a cancer treatment drug. ANDA ...
Bosutinib is a kinase inhibitor used in the treatment of adult patients with Philadelphia chromosome-positive chronic ...
Enliven Therapeutics (EVN) stock jumps as the company post initial early-stage trial data for its lead asset ELVN-001 in ...
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...
In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback